Canaccord raised the firm’s price target on Natera (NTRA) to $285 from $260 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they maintain the highest level of conviction in the risk-reward profile and share price appreciation potential for Natera.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera publishes findings from CALGB/SWOG 80702 study in JAMA Oncology
- NeoGenomics announce Natera withdrawal of appeal in patent litigation
- Natera price target raised to $260 from $250 at JPMorgan
- Natera price target raised to $205 from $190 at Wells Fargo
- Natera price target raised to $270 from $230 at Barclays